We examined the effects of the platelet-derived growth factor (PDGF) A-chain antisense oligodeoxynucleotides (ODN) on cardiovascular organ growth in stroke-prone spontaneously hypertensive rats (SHR-SP) in vivo. Expression of PDGF A-chain mRNA was higher in the aorta and kidney in 9-week-old SHR-SP than in Wistar-Kyoto (WKY) rats. A phosphorothioate-linked 15-mer antisense ODN complementary to the initiation codon region of rat PDGF A-chain mRNA and a control sense ODN were infused subcutaneously into SHR-SP/Izumo at a dose of 90 ng/g body weight/day for 28 days using an implanted ALZET pump. The PDGF A-chain antisense ODN did not affect blood pressure or body weight. The antisense ODN significantly inhibited [ 3 H]thymidine incorporation into the DNA in the aorta and kidney but not in the heart. Infusion of the antisense ODN considerably reduced production of PDGF A-chain protein but did not affect expression of PDGF A-chain mRNA. Infusion of the antisense ODN considerably improved the arterial and renal tissue damage in SHR-SP morphologically. From these findings, it can be confirmed that suppression of PDGF A-chain by the antisense DNA is useful as a gene therapy for treating cardiovascular organ damage in hypertension.
xaggerated growth of cardiovascular organs, which induces severe complications such as stroke, ischemic heart disease, and nephrosclerosis, is observed in patients with essential hypertension as well as in spontaneously hypertensive rats (SHR). 1 Platelet-derived growth factor (PDGF) has been implicated as a potent stimulator of vascular smooth muscle cells (VSMC) growth, exerting a proliferative as well as a mitogenic effect on cell growth. Three dimeric forms of PDGF are known: PDGF-AA, PDGF-AB and PDGF-BB. 2 Recently, PDGF A-chain mRNA was shown to accumulate in cultured VSMC from SHR in vitro and in aortic smooth muscle from SHR in vivo. 3, 4 Antisense DNA technology is useful for examining the function of a target gene or protein and may lead to new therapies for human diseases such as cancer, 5 leukemia, 6 viral infection, 7 and neointimal hyperplasia after arterial balloon injury. 8 We previously demonstrated that antisense oligodeoxynucleotides (ODN) to PDGF A-chain inhibits the exaggerated growth of VSMC from SHR in vitro and the arterial proliferation in SHR in vivo. 9 Stroke-prone spontaneously hypertensive rats (SHR-SP) provide a useful model for human malignant hypertension, which is characterized by exaggerated growth of cardiovascular organs and severe glomerulosclerosis. 10, 11 To evaluate the PDGF A-chain antisense ODN feasibility for treating cardiovascular organ damage in hypertension, we examined the effects of the PDGF A-chain antisense ODN on cardiovascular organ growth in SHR-SP in vivo.
Materials and Methods

ODN Synthesis
A phosphorothioate-linkaged 15-mer antisense ODN complementary to the rat PDGF A-chain mRNA initiation codon region (5Ј-AGGTCCTCATCGCGT) 12 and a control sense ODN (5Ј-ACGCGATGAGGACCT) were synthesized and phosphorothioate-linkaged 13 by a DNA synthesizer (model 394, Applied Biosystems, Foster, CA).
Experimental Protocol
Nine-week-old male SHR-SP/Izumo (Funabashi, Chiba, Japan) were randomly allocated into three groups. The sham group received an infusion of water (2.5 L/h) for 28 days using an ALZET pump (ALZA, Palo Alto, CA) implanted subcutaneously. The sense group received a subcutaneous infusion of sense ODN (90 ng/g body weight/day) using the pump for 28 days. The antisense group received a subcutaneous infusion of the antisense ODN (90 ng/g body weight/day) using the pump for 28 days. Systolic blood pressure (SBP) was measured by the tail-cuff method. Body weight was also determined before and every 7 days during the infusions.
Distribution of Antisense ODN to PDGF A-Chain in Vivo
Phosphorothioate-likaged synthetic antisense ODN was labeled with ␥-32 P-ATP (NEN Research Products, Wilmington, DE) by incubation with T 4 polynucleotide kinase (Toyobo, Osaka, Japan) in protruding-end kinase buffer (50 mmol/L Tris-HCl pH 8.0, 10 mmol/L MgCl 2 , and 10 mmol/L 2-mercaptoethanol).
32 P-labeled antisense ODN was separated by Sephadex G-25 column (Pharmacia LKB Biotechnology, Uppsala, Sweden) from free 32 P-ATP, washed, and precipitated with 75% ethanol.
32 P-labeled antisense ODN (100 ng, 8 ϫ 10 6 cpm) was dissolved in 400 L of distilled water and injected subcutaneously into 9-week-old male SHR-SP/Izumo (n ϭ 4). Twenty-four hours after the injection, the aorta, heart, and kidney were removed from rats anesthetized with pentobarbital. The removed organs were sufficiently washed with ice-cold saline to eliminate all blood and were weighed. Approximately 100 g of each tissue was homogenized in 1 mL of distilled water with Polytron PT-10 (Nihonseiki, Tokyo, Japan). A 50-L aliquot of homogenate in 10 mL of scintillation fluid was used to determine the 32 P-content. In addition, 200-L nucleic acids extract prepared from the homogenate by precipitation with 0.5 N perchloric acid and heating for 20 min at 90°C was counted to determine the amount of antisense ODN bound to nucleic acids.
Effect of PDGF A-Chain Antisense ODN on Cardiovascular Organ Growth
Organ growth was evaluated as described previously.
14 On day 28, the rats were weighed and injected with methyl [ 3 H]thymidine (0.66 Ci/g intraperitoneally, NEN Products, Boston, MA). Six hours after the injection, the aorta, heart, and kidney were removed. The organs were frozen immediately in liquid nitrogen, weighed, and stored at Ϫ80°C until assay. The organs were homogenized in 1 mL of distilled water with a Polytron PT-10 homogenizer (Nihonseiki, Tokyo, Japan). Aliquots of homogenate were taken for estimation of DNA content. In addition, an aliquot of homogenate was subjected to acid precipitation with 0.5 N perchloric acid and hydrolysis by heating for 20 min at 90°C and was then counted to determine [ 3 H]thymidine incorporation into the DNA ( 3 H-DNA).
Reverse Transcription and Polymerase Chain Reaction (RT-PCR) Assay of PDGF A-Chain mRNA
Vascular smooth muscles from approximately 1 cm of the aorta medial tissue from WKY/Izumo rats and SHR-SP/ Izumo were separated carefully from endothelium and adventitia using stainless steel oculidt forceps under a microscope. Approximately 50 mg of kidney sample was used only from cortex tissue, and approximately 50 mg of heart sample was used only from left ventricular tissue. These tissues were homogenized in 800 L of RNAzol B (Biotecx Laboratories, Houston, TX). Each sample was mixed with 80 L of chloroform, incubated at 4°C for 15 min, and centrifuged at 12 g for 15 min to extract the RNA. The RT-PCR technique was performed as described previously. 15 The 20-mer upstream sense primer (5Ј-AAGCATGTGCCGGAGAAGCG-3Ј) and 20-mer downstream antisense primer (5Ј-TCCTCTAACCTCACCTG-GAC-3Ј) were derived from the coding region of the rat PDGF A-chain cDNA. A 21-mer upstream sense primer (5Ј-CTGAAGGTCAAAGGGAATGTG-3Ј) and 21-mer downstream antisense primer (5Ј-GGACAGAGTCTT-GATGATCTC-3Ј) for the rat ribosomal protein L19 were included in the reaction as an internal control. 16 To confirm that no genomic DNA was coamplified by PCR, control experiments of the RT-PCR without reverse transcriptase using every set of primers were performed, in which no product was amplified. The PCR method was performed using a DNA Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT). For semiquantitative analysis of mRNA, the kinetics of the PCR reaction were monitored, and the number of cycles at which the PCR products became detectable on the gel was compared between the different samples.
17 Serial 10-fold dilutions of cDNA (100, 10, and 1 ng) were amplified; the PCR products became detectable at earlier cycles with increasing amounts of cDNA. The PCR method was performed for 30 cycles in an automatic thermocontroller (MJ Research, Watertown, MA) with the following thermal cycle profile: denaturing for 1 min at 96°C for 45 sec, primer annealing at 58°C for 45 sec, and primer extension at 72°C for 2 min. The PCR products were then electrophoresed through a 1.5% agarose gel and stained with ethidium bromide.
Western Blot Analysis for PDGF A-Chain Protein in Aorta and Kidney
Vascular smooth muscle from the aorta medial layer was collected as described in the previous section. Renal cortex kidney tissue (50 mg) was homogenized in 0.1 mol/L Tris-HCl, pH 9.0, and 10 mmol/L phenylmethyl sulfonyl fluoride and centrifuged at 10,000 g for 1 h. The protein concentration in the supernatant was determined by the method of Lowry et al, 18 and all extracts were adjusted to the same concentration. Western blot analysis used 10 L of the tissue extracts mixed with 20 L of sample buffer (63 mmol/L Tris-HCl pH 6.8, 2% SDS, 10% glycerol, and 5% 2-mercaptoethanol). The samples were boiled and subjected to 10% polyacrylamide gel electrophoresis. The proteins were transblotted to a nitrocellulose membrane and incubated with the polyclonal antibody specific for PDGF-AA (rabbit antihuman, Genzyme, Boston, MA) or the mouse monoclonal antibody specific for ␣-tubulin as a control (Sigma BioScience, St Louis, MO) diluted 1:500 in 5% nonfat milk in 10 mmol/L Tris-HCL, pH 8.0, 150 mmol/L NACL, and 0.05% Tween 20 (TBST) overnight at 4°C. The membrane was incubated with the goat antirabbit IgG for 1 h at room temperature and then washed with TBST three times for 5 min each. Immune complexes on the membrane were detected with protein A-gold (BioRad Laboratories, Richmond, CA) as described previously. 19 
Morphological Analysis for Glomeruli of Kidney From SHR-SP
The renal cortex kidney tissues were fixed in 4% formalin, and 4-m paraffin sections were stained with hematoxylin and eosin. To quantify mesangial cell number per glomerulus, all sections were evaluated by an observer with no knowledge of experimental treatments. A total of 20 glomeruli were selected at random in cross sections from each rat.
20
Statistical Analysis
Values are given as the means Ϯ SEM. The levels of significance of differences between the means were evaluated by Student t test for unpaired data and by two-way analysis of variance followed by Duncan's multiple range test.
Results
Expression of PDGF A-Chain mRNA in Cardiovascular Organs From SHR-SP
Basal abundance of PDGF A-chain mRNA in the medial aorta layer and kidney cortex tissue from 9-week-old SHR-SP were significantly (P Ͻ .01) higher than those from age-matched WKY rats (Fig. 1) . Expression of PDGF A-chain mRNA was not detected in heart tissue from SHR-SP (data not shown).
Effects of PDGF A-Chain Antisense ODN on SBP and Body Weight
To determine the effects of ODN infusion on physiological parameters, we measured SBP and body weight in three groups of SHR-SP during ODN infusion. There was no difference in SBP or body weight between the control and experimental groups during a 4-week period (data not shown).
In Vivo Distribution of 32 P-Antisense ODN to PDGF A-Chain
The percentage of total injected 32 P-labeled antisense ODN taken up into the organs analyzed and their nucleic acids 24 h after the injection are summarized in Table 1 . In all, 0.002%, 0.2%, and 0.8% of the total 32 P-antisense ODN were detected in the nucleic acids in the aorta, heart, and kidney, respectively.
Effects of PDGF A-Chain Antisense ODN on Growth of Cardiovascular Organs
We also assessed the effects of PDGF A-chain antisense ODN on the growth of cardiovascular organs in SHR-SP by determining the total and [ 3 H]-DNA content of the aorta, heart, and kidney after ODN infusion in our three groups. Kidney DNA content was significantly lower (P Ͻ .01) in the antisense than in the sense group. [ 3 H]-DNA in the aorta and kidney were significantly lower in the antisense than in the sense group (P Ͻ .01). There was no difference in total or [ 3 H]-DNA content in the heart in the antisense and sense groups after the ODN infusion (Fig. 2) .
Effects of PDGF A-Chain Antisense ODN on Expression of PDGF A-Chain mRNA in Aorta and Kidney
There was no difference in the abundance of PDGF Achain mRNA in the aorta and kidney among the sham, sense, and antisense groups (data not shown).
Effects of PDGF A-Chain Antisense ODN on Expression of PDGF A-Chain Protein in Aorta and Kidney
Antisense ODN infusion considerably reduced the abundance of the 17 kDa PDGF A-chain protein in the aorta (Fig. 3A) and kidney (Fig. 3B ) from SHR-SP as evaluated by Western blot analysis, whereas sense ODN infusion did not affect the abundance of PDGF A-chain protein in the aorta and kidney. These data are representative of three separate experiments. Fig. 4 shows morphological changes and their quantitative determination of mesangial cell proliferation indices in kidney cortex in the sham, sense, and antisense SHR-SP groups. Glomeruli proliferation was seen in the three groups. The degree of proliferation in the antisense groups was less than that in the sham and sense groups. In arteries and arterioles, the degree of onion-skin appearance and arteriolar necrosis was similar among the three groups (Fig. 4A) . The mesangial cell count in the antisense groups was significantly (P Ͻ .05) lower than that in the sham and sense groups (Fig. 4B) .
Effects of PDGF A-Chain Antisense ODN on Morphological Changes in Kidney
Discussion
To verify the feasibility of PDGF A-chain antisense ODN for treating hypertension, we examined the effect of antisense ODN on the growth of cardiovascular organs in SHR-SP. The SHR-SP is considered to be a model of PDGF A ϭ platelet-derived growth factor; SHR-SP ϭ stroke-prone spontaneously hypertensive rats. Note: A total of 100 ng of 32 P-labeled antisense oligodeoxynucleotide (ODN) was subcutaneously injected into stroke-prone spontaneously hypertensive rats (SHR-SP). Aorta, heart, and kidney were removed 24 h after the injection and homogenized.
32 P-content was determined in aliquots of homogenates and nucleic acids extract prepared from the homogenate. Values are calculated as percentages of total 32 P-antisense ODN injected and expressed as means Ϯ SE.
human malignant hypertension with severe complications in cardiovascular organs, including renal dysfunction. 10, 11 The renal dysfunction in SHR-SP results from the development of nephrosclerosis. However, the mechanism underlying the nephrosclerosis in SHR-SP remains unclear. Reportedly, several kidney growth factors such as TGF-␤ 21 and PDGF 22 play important roles in the progression of nephrosclerosis. Immunocytochemical studies have shown that renin-angiotensin system is present in rat and human kidney. 23 Several investigators have demonstrated that angiotensin converting enzyme (ACE) inhibitors 24 and angiotensin II type 1 (AT1) receptor antagonists 25 mediate the progression of renal damage in SHR-SP. Kim et al 26 demonstrated that an AT1 receptor antagonist decreased renal TGF-␤ mRNA levels in SHR-SP, suggesting that increases in renal TGF-␤ mRNA in SHR-SP are associated with the renal renin-angiotensin system. In addition, TGF-␤ induces PDGF A-chain gene expression. 27 Because TGF-␤ induces PDGF A-chain gene expression (which, in turn, stimulates cellular growth), PDGF Achain protein is a final growth factor needed to cause nephrosclerosis. In this study, the SHR-SP kidney tissue increasingly expressed PDGF A-chain mRNA. In addition, the PDGF A-chain antisense ODN inhibited DNA synthesis in SHR-SP kidney and improved the glomerulosclerotic morphological change, suggesting that PDGF A-chain plays critical roles in glomerulosclerosis.
In the present study, 32 P-labeled phosphorothioate-linkaged antisense ODN entered the cells and combined with the nucleic acid fraction. The uptake of 32 P-labeled antisense ODN was higher in the aorta than in other organs. This suggests that arterial tissue expresses higher levels of PDGF A-chain mRNA, which may then hybridize with the antisense ODN. In the aorta and kidney in SHR-SP, the antisense ODN inhibited PDGF A-chain protein production but the sense ODN did not, suggesting that the antisense ODN inhibitory effect was specific for the PDGF A-chain. However, the antisense ODN did not affect PDGF A-chain mRNA expression in the aorta or kidney. We also previously demonstrated that antisense ODN to PDGF A-chain containing mutations reduced the antisense ODN-induced inhibition of DNA synthesis in SHR-de- 3 H]-DNA of (A) aorta, (B) heart, and (C) kidney. Sham infusion group (Sham) was given subcutaneous infusion of water for 28 days. Sense and antisense groups were given subcutaneous infusion of sense and antisense ODN, respectively (90 ng/g body weight/day), using the pump, for 28 days. Data are expressed as mean Ϯ SEM (n ϭ 4). *P Ͻ .01 between sense and antisense groups. rived VSMC, indicating that growth inhibition by antisense ODN to PDGF-A chain acts in a hybridizationdependent manner. 9 These findings suggest that the antisense ODN hybridizes specifically with PDGF A-chain mRNA to prevent a translation into PDGF Achain protein without transcription attenuation.
Nephrosclerosis in human hypertension is a severe clinical complication. However the nephrosclerosis therapies in hypertension are still insufficient. Akagi et al 19 recently reported that inhibition of TGF-␤ expression by an antisense ODN suppressed extracellular matrix accumulation in experimental glomerulonephritis. When antisense ODN side effects have been eliminated and drug delivery systems established, antisense therapy for hypertension especially with nephrosclerosis may become clinically useful.
FIG. 4. A)
Morphological changes in kidney cortex in stroke-prone spontaneously hypertensive rats with antisense oligodeoxynucleotide (ODN) to platelet-derived growth factor A-chain. Sham infusion group was given subcutaneous infusion of water for 28 days. Sense and antisense groups were given subcutaneous infusion of sense and antisense ODN, respectively (90 ng/g body weight/day), using the pump, for 28 days. B) Quantification of morphological changes in stroke-prone spontaneously hypertensive rats with antisense oligodeoxynucleotide (ODN) to platelet-derived growth factor A-chain. Sense and antisense groups were given subcutaneous infusion of sense and antisense ODN, respectively, (90 ng/g body weight/day), using the pump, for 28 days. To quantify mesangial cell number per glomerulus, all sections were evaluated by an observer with no knowledge of experimental treatments. A total of 20 glomeruli were selected at random in cross sections from each rat. Data are expressed as mean Ϯ SEM (n ϭ 20). *P Ͻ .05 between sense and antisense groups.
